Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Dow
Harvard Business School
Medtronic
Merck

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

COSOPT Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Drug patent expirations by year for COSOPT
Drug Prices for COSOPT

See drug prices for COSOPT

Drug Sales Revenue Trends for COSOPT

See drug sales revenues for COSOPT

Recent Clinical Trials for COSOPT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of FloridaPhase 1
Mid Atlantic RetinaPhase 2/Phase 3
Wills EyePhase 2/Phase 3

See all COSOPT clinical trials

Recent Litigation for COSOPT

Identify potential future generic entrants

District Court Litigation
Case NameDate
MERCK & CO., INC. v. APOTEX INC.2006-12-04
MERCK & CO., INC. v. HI-TECH PHARMACAL CO., INC.2006-01-18

See all COSOPT litigation

Synonyms for COSOPT
(4S,6S)-4-(Ethylamino)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide 7,7-dioxide, monohydrochloride
(4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide hydrochloride
(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide hydrochloride
(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide;hydrochloride
130693-82-2
279D961
4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, monohydrochloride, (4S-trans)-
4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 5,6-dihydro-4-(ethylamino)-6-methyl-, 7,7-dioxide, monohydrochloride, (4S,6S)-
ABP001060
AC-5244
AC1OCF25
AKOS005146235
AKOS015895951
API0007146
BC208520
C10H16N2O4S3.HCl
CAS-130693-82-2
CC-27373
CCG-221116
CHEBI:4703
CHEMBL1201162
CS-1858
CTK8E7974
D00653
D4189
Dorzolamide (hydrochloride)
Dorzolamide for system suitability, European Pharmacopoeia (EP) Reference Standard
Dorzolamide HCl
Dorzolamide HCl salt
DORZOLAMIDE HYDROCHLORIDE
Dorzolamide hydrochloride (JP17/USP)
Dorzolamide hydrochloride [USAN:USP]
Dorzolamide hydrochloride, European Pharmacopoeia (EP) Reference Standard
Dorzolamide hydrochloride, United States Pharmacopeia (USP) Reference Standard
Dorzolamide impurity A
Dorzolomide hydrochloride
DSSTox_CID_25530
DSSTox_GSID_45530
DSSTox_RID_80933
DTXSID1045530
FT-0082547
FT-0631133
HMS1571O14
HY-B0109A
I06-1271
J10249
K-4065
KB-50425
KS-00000XJI
KS-1348
L 671152
L-671,152
L-671152
MK 0507
MK-0507
MK-507
MLS002154162
MolPort-005-935-141
NCGC00016977-01
NCGC00179244-03
OSRUSFPMRGDLAG-QMGYSKNISA-N
QZO5366EW7
RTC-070963
s1375
SC-18010
SCHEMBL41152
SMR001233461
SR-05000001449
SR-05000001449-3
TC-070963
Tox21_110720
Tox21_110720_1
Trusopt
Trusopt (TN)
UNII-QZO5366EW7
Paragraph IV (Patent) Challenges for COSOPT
Tradename Dosage Ingredient NDA Submissiondate
COSOPT SOLUTION/DROPS;OPHTHALMIC dorzolamide hydrochloride; timolol maleate 020869 2005-10-11

US Patents and Regulatory Information for COSOPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc COSOPT dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 020869-001 Apr 7, 1998 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
Oak Pharms Inc COSOPT PF dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 202667-001 Feb 1, 2012 AT RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COSOPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Oak Pharms Inc COSOPT dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 020869-001 Apr 7, 1998   Start Trial   Start Trial
Oak Pharms Inc COSOPT dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 020869-001 Apr 7, 1998   Start Trial   Start Trial
Oak Pharms Inc COSOPT dorzolamide hydrochloride; timolol maleate SOLUTION/DROPS;OPHTHALMIC 020869-001 Apr 7, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Dow
Express Scripts
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.